GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » 3-Year FCF Growth Rate

Galmed Pharmaceuticals (Galmed Pharmaceuticals) 3-Year FCF Growth Rate : 50.80% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals 3-Year FCF Growth Rate?

Galmed Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.18.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 50.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 15.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Galmed Pharmaceuticals was 50.80% per year. The lowest was -65.10% per year. And the median was -1.30% per year.


Competitive Comparison of Galmed Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Galmed Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's 3-Year FCF Growth Rate falls into.



Galmed Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Galmed Pharmaceuticals  (NAS:GLMD) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Galmed Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.